Abstract
Three FDA-approved epidermal growth factor receptor (EGFR) antibodies (cetuximab, panitumumab, necitumumab) are clinically available to treat patients......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
